After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

A still from the 2025 Super Bowl commercial “Sick of the System,” from telehealth company Hims & Hers. © 2024 Fortune Media IP Limited. All Rights Reserved. Use ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of worsening kidney disease in people with type 2 diabetes. The approval ...

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug for weight management. The Food and Drug Administration’s approval ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Wegovy (semaglutide) has a list ... drugs. Novo Nordisk, too, joined in the backlash, calling the commercial “irresponsible” and a ploy to drive sales of “knockoff” GLP-1 drugs.

“These exorbitant costs have made it extremely challenging to be able to continue to provide drug coverage to everyone who wants these drugs but does not have an FDA-approved medical condition ...